⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860713 | 0.75 | — | — | |
| SCHEMBL891574 | 0.73 | — | — | |
| SCHEMBL2000632 | 0.73 | CES1 (0.30) | — | |
| Water SCHEMBL3825332 | 0.71 | — | — | |
| SCHEMBL15511662 | 0.71 | CASP1 (0.36) | — | |
| SCHEMBL5861833 | 0.69 | — | — | |
| SCHEMBL9886064 | 0.69 | CASP1 (0.33) | — | |
| SCHEMBL4932569 | 0.69 | LIPA (0.38) | — | |
| SCHEMBL5861742 | 0.69 | — | — | |
| SCHEMBL15695436 | 0.67 | CASP1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4400 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977918-A | Synthesis method of 2-bromomethyl-5-trifluoromethyl furan | 上海高准医药有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-109400589-B | Quinoxaline bactericide, preparation method and application thereof | 湖北文理学院 | 2020-09-25 | — | — | CN | claimed |
| JP-7165750-A | — | — | None | — | — | JP | disclosed |
| EP-3620473-B1 | NOVEL HETERODIMERIC PROTEINS | XENCOR INC (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748862-A2 | HETERODIMERIC PROTEINS | Xencor, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3865514-B9 | BISPECIFIC ANTIBODY BINDING DLL3 AND CD3 | AMGEN RES MUNICH GMBH (DE) | 2026-05-20 | — | — | EP | disclosed |
| US-12630650-B2 | Engineered IgA antibodies and methods of use | TIGATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260132199-A1 | ANTIBODY CONSTRUCTS FOR DLL3 AND CD3 | AMGEN RES MUNICH GMBH (DE) | 2026-05-14 | — | — | US | disclosed |
| EP-4741424-A2 | FC VARIANTS WITH ALTERED BINDING TO FCRN | Xencor, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| CN-122029189-A | Anti-SARS-CoV-2 spike (S) antibodies and their use in treatment COVID-19 | 诺瓦瓦克斯股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-3817770-B1 | ANTI-STEAP1 ANTIGEN-BINDING PROTEIN | AMGEN INC (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-1990013643-A2 | GLYCOPROTEIN HORMONE RECEPTOR MOLECULES | GENENTECH, INC. (US) | 1990-11-15 | — | — | WO | disclosed |
| WO-1990010453-A1 | USE OF INTERCELLULAR ADHESION MOLECULES, AND THEIR BINDING LIGANDS IN THE TREATMENT OF ASTHMA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1990-09-20 | — | — | WO | disclosed |
| EP-0387701-A1 | Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma | Boehringer Ingelheim Pharmaceuticals Inc. (US) | 1990-09-19 | — | — | EP | disclosed |
| WO-1990007572-A1 | HUMAN DNase | GENENTECH, INC. (US) | 1990-07-12 | — | — | WO | disclosed |
| EP-0362272-A1 | METHOD AND COMPOSITIONS FOR MAKING ACSF AND ACSF ANTAGONISTS. | GENENTECH INC (US) | 1990-04-11 | — | — | EP | disclosed |
| EP-0354989-A1 | Megakaryocytopoietin, preparation and use | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1990-02-21 | — | — | EP | disclosed |
| WO-1989012678-A1 | PURIFIED UBIQUITIN HYDROLASE, DNA SEQUENCES ENCODING SAME, AND ITS USE IN RECOVERING POLYPEPTIDES | GENENTECH, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
| WO-1988009376-A1 | METHOD AND COMPOSITIONS FOR MAKING ACSF AND ACSF ANTAGONISTS | GENENTECH, INC. (US) | 1988-12-01 | — | — | WO | disclosed |
| US-4562292-A | INHIBITORS OF HYDROLYTIC ENZYMES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1985-12-31 | — | — | US | disclosed |